Advertisement

Clinical & Translational Oncology

, Volume 8, Issue 4, pp 266–270 | Cite as

Whole brain irradiation and temozolomide based chemotherapy in melanoma brain metastases

  • Carlos ConillEmail author
  • Sandra Jorcano
  • Josep Domingo-Doménech
  • Rosa Gallego
  • Josep Malvehy
  • Susana Puig
  • Marcelo Sánchez
  • Ramón Vilella
  • Teresa Castel
Research Articles

Abstract

Introduction

Whole brain irradiation (WBRT) remains a recommended treatment for patients with brain metastases from malignant melanoma in terms of symptom palliation, especially when extracranial systemic disease is present. Temozolomide (TMZ) has shown efficacy in the treatment of metastatic melanoma. The objective was to evaluate the potential benefit in survival of two different schedules of total dose and fractionation (20 Gy/5 fractions vs 30 Gy/10 fractions) and further TMZ based chemotherapy.

Materials and method

We have conducted a retrospective study in a group of twenty-one patients (RTOG Recursive Partitioning Analysis class II) of the use of WBRT with 20 Gy/5 fractions (n=11) and 30 Gy/10 fractions (n=10). All patients received further TMZ based chemotherapy administered as a single chemotherapeutic agent or in combination with chemo-immunotherapy.

Results

Prognostic variables such as: age, Karnofsky performance status, extracranial metastases and number of brain metastases, were analyzed in both groups of treatment without statistically significant differences. The median survival time (MST) for WBRT 20 Gy group was 4 months (CI 95%: range 2–6 months) and for WBRT 30 Gy group was 4 months (CI 95%: range 0–7 months) without statistically significant differences (Log rank p=0.74). There was one complete response and two partial responses.

Conclusions

The results suggest that MST was not significantly affected by the total dose/fractionation schedule.

Key words

malignant melanoma brain metastases radiotherapy chemotherapy temozolomide 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Madajewicz S, Karakousis C, West CR, Caracandas J, Avellanosa AM. Malignant melanoma brain metastases. Review of Roswell Park Memorial Institute experience. Cancer. 1984;53:2550–2.PubMedCrossRefGoogle Scholar
  2. 2.
    Chao JH, Phillips R, Nickson JJ. Roentgen-ray therapy of cerebral metastases. Cancer. 1954;7:682–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Carella RJ, Gelber R, Hendrickson F, Berry HC, Cooper JS. Value of radiation therapy in the management of patients with cerebral metastases from malignant melanoma: Radiation Therapy Oncology Group Brain Metastases Study I and II. Cancer. 1980;45:679–83.PubMedCrossRefGoogle Scholar
  4. 4.
    Buchsbaum JC, Suh JH, Lee S-Y, Chidel MA, Greskovich JF, Barnett GH. Survival by Radiation Therapy Oncology Group Recursive Partitioning Analysis Class and treatment modality in patients with brain metastases from malignant melanoma. A retrospective study, Cancer. 2002;94:2265–72.PubMedCrossRefGoogle Scholar
  5. 5.
    Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol. 1999;17:2762–71.PubMedGoogle Scholar
  6. 6.
    Bleehen NM, Newlands ES, Lee SM, et al. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol. 1995;15:910–3.Google Scholar
  7. 7.
    Franke W, Neumann N, Richter-Hintz D, Ruzicka T, Klaus W. Temozolomide-A promising agent in the therapy of brain metastases in malignant melanoma. In: American Society of Clinical Oncology 36th Annual Meeting, New Orleans, May 20–23, 2000, Prog Proc Am Soc Clin Oncol. 2000;19:575.Google Scholar
  8. 8.
    Biasco G, Pantaleo MA, Casadei S. Treatment of brain metastases of malignant melanoma with temozolomide. N Engl J Med. 2001;345:621.PubMedCrossRefGoogle Scholar
  9. 9.
    Conill C, Puig S, Toscas I, Castel T. Complete response of cerebral metastasic melanoma after a combined treatment of radiotherapy and temozolomide. Med Clin (Barc). 2002;119(19):758–9.Google Scholar
  10. 10.
    Conill C, Fernández-Ibiza J, Malvehy J, Puig S, Sánchez M, Castel T. Temozolomide in patients with melanoma brain metastases treated with whole brain irradiation. Med Clin (Barc). 2004;122:413–5.CrossRefGoogle Scholar
  11. 11.
    Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH. The use of nitrogen mustards in the palliative treatment of cancer. Cancer. 1948;1:634–56.CrossRefGoogle Scholar
  12. 12.
    Conill, C, Verger E, Salamero M. Performance status assessment in cancer patients. Cancer. 1990;65:1864–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Gaspar LE, Scott Ch, Murray K, Curran W. Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys. 2000;47:1001–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Ellerhorst J, Strom E, Nardone E, McCutcheon I. Whole brain irradiation for patients with metastatic melanoma: a review of 87 cases. Int J Radiat Oncol Biol Phys. 2001;49:93–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Konefal JB, Emami B, Pilepich MV. Analysis of dose fractionation in the palliation of metastases from malignant melanoma. Cancer. 1988;61:243–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Bafaloukos D, Tsoutsos D, Fountzilas G, et al. The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma. Melanoma Research. 2004;14:289–94.PubMedCrossRefGoogle Scholar
  17. 17.
    Ulrich J, Gademann G, Gollnick H. Management of cerebral metastases from malignant melanoma: results of a combined, simultaneous treatment with fotemustine and irradiation. J Neuro Oncol. 1999;43: 173–8.CrossRefGoogle Scholar
  18. 18.
    Mornex F, Thomas L, Mohr P, et al. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Research. 2003;13:97–103.PubMedCrossRefGoogle Scholar
  19. 19.
    Margolin K, Atkins MB, Thompson JA, et al. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: A phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol. 2002;128:214–8.CrossRefGoogle Scholar
  20. 20.
    Paul MJ, Summers Y, Calvert AH, et al. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res. 2002; 12:175–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Conill C, González-Cao M, Jorcano S, et al. Temozolomide as prophylaxis for melanoma brain metastases. Melanoma Res. 2004;14:73–4.PubMedCrossRefGoogle Scholar
  22. 22.
    Conill C, Jorcano S, Pujol T, Malvehy J. Radiation leukoencephalopathy. Clinical and radiological evolution. Med Clin (Barc). 2004;125:437.CrossRefGoogle Scholar

Copyright information

© FESEO 2006

Authors and Affiliations

  • Carlos Conill
    • 1
    Email author
  • Sandra Jorcano
    • 1
  • Josep Domingo-Doménech
    • 2
  • Rosa Gallego
    • 2
  • Josep Malvehy
    • 3
  • Susana Puig
    • 3
  • Marcelo Sánchez
    • 4
  • Ramón Vilella
    • 5
  • Teresa Castel
    • 3
  1. 1.Department of Radiation Oncology Hospital Clinic. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)University of barcelonaBarcelonaSpain
  2. 2.Department of Medical Oncology Hospital Clinic. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)University of BarcelonaBarcelonaSpain
  3. 3.Department of Dermatology Hospital Clinic. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)University of BarcelonaBarcelonaSpain
  4. 4.Department of Radiodiagnostics Hospital Clinic. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)University of BarcelonaBarcelonaSpain
  5. 5.Department of Immunology Hospital Clinic. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)University of BarcelonaBarcelonaSpain

Personalised recommendations